Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.1111/ane.12490</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:33788489">http://nrs.harvard.edu/urn-3:HUL.InstRepos:33788489</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP</a></td>
</tr>
</tbody>
</table>
Bevacizumab Treatment for Symptomatic Spinal Ependymomas in Neurofibromatosis

Type 2

S. Farschtschi¹ MD, V.L. Merker² MD, D. Wolf³ MD, M. Schuhmann⁴ MD, †J. Blakeley³ MD, ‡S.R. Plotkin² MD PhD, ‡C. Hagel⁵ MD, ‡V.F. Mautner¹ MD

†These four authors contributed equally to the publication

Affiliations:
1. University Medical Center Hamburg-Eppendorf, Department of Neurology, Martinistr. 52, 20246 Hamburg, Germany
2. Massachusetts General Hospital, Pappas Center for Neuro Oncology. 55 Fruit Street, Boston, MA 02114, USA
3. The Johns Hopkins Hospital, Department of Neurology, 1550 Orleans Street, Baltimore, MD 21231, USA
4. University Medical Center Tübingen, Department of Neurosurgery, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany
5. University Medical Center Hamburg-Eppendorf, Institute of Neuropathology, Martinistr. 52, 20246 Hamburg, Germany

Corresponding Author:
Said Farschtschi
Martinistr. 52
20246 Hamburg
Germany
Phone: +4940-7410-55629
Fax: +4940-7410-55966
E-mail: s.farschtschi@uke.de

Word Count: 1490
Keywords: Neurofibromatosis, ependymoma, bevacizumab, NF2, VEGF
Short Title: Bevacizumab for Symptomatic Spinal Ependymomas in NF2
Abstract

Background: Neurofibromatosis type 2 (NF2) is a tumor suppressor syndrome associated with vestibular schwannomas, meningiomas, and spinal ependymomas. There have been anecdotal reports of radiographic response of spinal ependymomas in NF2 patients being treated for progressive vestibular schwannomas with bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF).

Aims: To review the clinical effects of bevacizumab treatment for symptomatic, NF2-associated ependymomas

Methods: We conducted a retrospective review of all patients with NF2 treated with bevacizumab for symptomatic ependymoma at three NF2 specialty centers. Tumor size was evaluated by linear measurements; radiographic response was defined as >20% reduction in tumor size. We also performed immunohistochemical evaluation of NF2-associated symptomatic ependymomas from 5 patients, including 2 from this clinical series.

Results: Eight patients with NF2 and symptomatic ependymoma were treated with bevacizumab. All patients had subjective clinical improvement with bevacizumab, although only 5/8 patients evaluated had radiographic response. All tumors expressed VEGF-R2. 4/5 evaluated ependymomas expressed VEGF-R1; one without VEGF-R1 expression was from a patient who showed clinical but no radiographic response.

Conclusions: Treatment using bevacizumab improved symptoms related to NF2-associated ependymomas, often without concurrent radiographic response. This treatment effect may be related to VEGF-R1 expression in NF2-associated ependymoma.
Introduction

Neurofibromatosis type 2 (NF2) is a neurogenetic tumor predisposition disorder with an incidence of ~1:27,000. Hallmark lesions of NF2 include bilateral vestibular schwannomas, non-vestibular schwannomas and meningiomas. In addition, an estimated 33% of patients with NF2 have spinal ependymomas (4). Histopathology of these lesions includes tanycytic and myxopapillary (WHO grade 1) and classic (WHO grade 2) ependymoma; signs of anaplasia are uncommon (4;5). In contrast to their sporadic counterparts, ependymomas in NF2 appear almost exclusively in the spinal cord and are characterized by multi-segment tumor formation with large cystic compartments.

In most NF2 patients, spinal ependymomas are asymptomatic and therapy is not required; however, in about one-fourth of patients with ependymomas, tumors can cause significant neurological symptoms. Currently, the most common treatment for NF2-related symptomatic ependymomas is surgical resection. However, surgery has a high risk of spinal cord injury and perioperative complications, especially in patients exhibiting severe neurological symptoms such as paraparesis or sensory loss prior to surgery (4). For this reason, chemotherapeutic options for treatment are highly desirable.

Recent investigations have revealed potentially promising effects of bevacizumab on NF2-related vestibular schwannomas (9). Bevacizumab is a recombinant humanized monoclonal antibody against vascular endothelial growth factor (VEGF-A). Neutralization of VEGF may lead to inhibition of tumor growth, decreases in interstitial fluid pressure, and increased tumor oxygenation.

The effect of bevacizumab on ependymomas has not been established. In a small case series, 87.5% of adults with sporadic, recurrent ependymoma achieved either a partial response
or stable disease after treatment with bevacizumab (alone or in combination with cytotoxic chemotherapy) (11). However, in sporadic recurrent ependymoma in children, bevacizumab and irinotecan failed to show any sustained response (12). A report on the effect of bevacizumab in NF2 patients being treated for progressive vestibular schwannoma suggested an effect on spinal ependymomas (13), but to date, no studies have systematically addressed the response of symptomatic spinal ependymomas to bevacizumab in NF2. Here we report the clinical effect of bevacizumab on ependymomas in 8 patients with NF2, and VEGF receptor expression in 5 resected, NF2-related ependymomas.

Methods

All patients were diagnosed with NF2 by experienced clinicians based on consensus criteria. Patients received bevacizumab as treatment for symptomatic ependymoma after consulting neurosurgeons deemed them poor candidates for surgery or they refused surgical treatment. Using MRIs of the head and spine performed with intravenous gadolinium contrast, we measured ependymoma size (in mm) using T2-weighted images with radiographic response was defined as ≥20% reduction in linear measures. Volumetric assessment of ependymomas was not feasible due to the inhomogeneous appearance and cystic tumor formation. We measured vestibular schwannoma volume (in cm³) using T1 post-contrast images, with radiographic response defined as ≥20% reduction in volume. Clinical and radiological follow up were performed routinely every 6 to 12 months.

Immunohistochemistry: Three NF2-associated ependymomas from a case series previously reported by Hagel et al. (5) were available for immunohistochemical evaluation of VEGF-R1 and
VEGF-R2. In addition, pre-treatment surgical specimens from patients 3 and 5 of this case series were also analyzed for VEGF-R1 and R2. Immunohistochemical studies used four micrometer thick sections. Tissue sections were heat pre-treated followed by incubation with VEGFR-1 or VEGFR-2 antibodies (Santa Cruz sc-316, 1:100; Santa Cruz sc-504, 1:50) in an automated stainer (Ventana Medical Systems, Tucson, AZ, USA) according to standard protocols. Bound antibodies were detected by the peroxidase method using diaminobenzidine as chromogen (760-500, Ultraview DAB, Ventana). All antibody reactions were validated prior to the study using isotype negative-controls and glioblastoma samples harboring pathological endothelial proliferations as positive controls (data not shown).

3. Results

3.1 Patient characteristics: 8 patients (7 male, 1 female) from three institutions were treated with bevacizumab for symptomatic spinal ependymomas (Table 1). Median age at time of treatment was 22 years (range 15-34 years). Symptoms prompting treatment included dysphagia, ataxic gait, spastic paraparesis and intractable pain. Two patients underwent surgery prior to bevacizumab treatment (patient 3 and 5), with pathological confirmation of the diagnosis of ependymoma; for all other patients, diagnosis of ependymoma was made based on characteristic radiographic appearance. Seven patients had radiographically documented ependymoma growth prior to treatment.

3.2 Bevacizumab treatment: The initial dose of bevacizumab was either 5 or 7.5 mg per kg every 2 weeks. In some patients, the dose was decreased during the course of treatment to minimize long term toxicity; four patients received 3.75 mg/kg every two weeks and four
patients received 7.5-10 mg/kg every three weeks. The median duration of treatment was 13.5 months (range 6-58 months).

3.3 Clinical and radiographic response: All eight patients had subjective improvement in neurologic function as rated both by the patient and the care team. Improved neurological symptoms included dysphagia (#1-2), sensory deficits (#3-8), weakness (#3-6), bladder and bowel dysfunction (#3), pain (#3, 6-8), and ataxia (#4-6).

Half of patients experienced radiographic response of ependymoma, seen within 3 to 6 months after treatment initiation. In all four patients with a radiographic response (#4-7), the cystic compartments of the ependymoma demonstrated the greatest decrease in size. Importantly, there were no instances of pseudoresponse – the resolution of contrast enhancement – noted in any patients. (14) There was no obvious relationship between the degree of tumor shrinkage and perceived clinical benefit. For example, patient 3, who showed no significant radiographic change in tumor size, demonstrated improvement of ataxia, paraparesis and urinary incontinence such that he regained bladder control and ambulation.

3.4 Treatment breaks: In 5/8 patients, treatment was held for ≥6 months. In three patients (#1,4,& 7), symptomatic improvements noted during treatment were lost during treatment hold, but returned within a few months when drug was re-started. Radiographic progression was noted in patient 4 during treatment hold (Fig. 1), but was followed by a reduction of tumor size to the baseline volume after restarting bevacizumab. After stopping treatment, patient 2 and 8 presented with radiological relapse and increasing back pain.

3.5 Toxicity: Toxicity related to bevacizumab treatment was mild. One patient had a single episode of abdominal pain with hematochezia for which bevacizumab was held for 2
months. Symptoms improved, work-up was negative, and he was able to resume drug without complication. There were no grade 3 or 4 adverse events related to bevacizumab.

3.6 Immunohistochemistry: Upon immunohistochemical investigation, all tumors investigated showed expression of VEGF-R2 in all parts of the tumor (Fig. 2). 4/5 tumors showed expression of VEGFR-1 in tumor cells, and in 2/5 cases, the receptor was detected in endothelial cells. Staining ranged from scattered single cells over patchy expression to strong labeling of large tumor areas (Fig. 3). In one case, (patient 3) the staining was negative. This patient experienced clinical improvement but no radiographic response.

Discussion

This is the first case series to investigate the effect of bevacizumab on symptomatic spinal ependymomas in patients with NF2. All eight patients showed clinical improvement, despite significant neurological impairments at baseline. Continued treatment with bevacizumab was necessary to maintain neurological improvement. In our experience, clinical and radiographic improvement occurred within 3 to 6 months of treatment and clinical relapse occurred about 6 months after treatment discontinuation. Interestingly, some individuals had discordant radiographic changes in vestibular schwannomas and ependymoma, pointing to the heterogeneity of NF2-related tumors.

Shrinkage of tumors was primarily noted in the cystic portions of ependymomas, suggesting that the primary effect of bevacizumab is on vascular permeability rather than on tumor cells. The clinical improvement after treatment onset may be explained by an anti-edema effect of bevacizumab. In previous studies on vestibular schwannoma treated with bevacizumab,
there was a correlation between tumor shrinkage and change in the apparent diffusion coefficient value, a radiological marker for edema (8).

We found a slight endothelial expression and strong tumor tissue expression of VEGFR-1 in 4/5 NF2-associated spinal ependymomas. Our findings agree with that of Chan et al. (15), who reported that 5/6 sporadic ependymomas investigated by in-situ-hybridization for VEGFR-1 and VEGFR-2 expression had slight to strong expression of mRNA of both receptors.

From our case series, patient 3 showed no significant expression of VEGF-R1 prior to treatment, which could explain the lack of radiographic response in this patient. However, this patient still displayed significant clinical improvement despite the lack of tumor shrinkage. For this reason, we believe that clinical improvement, rather than radiographic response, should be used to assess the benefit of bevacizumab for patients with NF2.

Because of the small sample size, our data cannot be generalized to all NF2 patients with symptomatic spinal ependymomas. Ependymomas were evaluated by linear measures and not by volumetric measurement, so small changes in tumor size might not have been detected. The patients presented in this case series were selected for bevacizumab treatment due to severe symptoms associated with their spinal ependymomas; however, many NF2 patients with ependymomas have few or no clinical impairments, making drug treatment unnecessary.

Taken together, these findings suggest bevacizumab improves clinical symptoms related to NF2-related spinal ependymoma in selected patients, with a less robust effect on tumor size. Further investigation is warranted to study the mechanisms and potential benefit of bevacizumab as a novel option for treatment of symptomatic ependymomas in NF2 patients.

**Conflicts of interest:** The authors declare they have no conflicts of interest.
**Sources of funding:** No funding

**Acknowledgment:** None

**Declaration:** This study was conducted in full accordance with the declaration of Helsinki.
Reference List


Table 1. Patient characteristics

<table>
<thead>
<tr>
<th>Patient</th>
<th>Gender</th>
<th>Age at Treatment</th>
<th>Age at Diagnosis</th>
<th>Treatment Indication</th>
<th>Ependymoma Location</th>
<th>Pre-treatment Ependymoma Growth</th>
<th>Treatment Duration (months)</th>
<th>Treatment Hold ≥ 6 months</th>
<th>Average Dose</th>
<th>Radiographic Response VS</th>
<th>Radiographic Response Ependymoma</th>
<th>Clinical Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>m</td>
<td>22</td>
<td>6</td>
<td>dysphagia/airway</td>
<td>cervical</td>
<td>Yes</td>
<td>8</td>
<td>Yes</td>
<td>7.5 q3</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>m</td>
<td>15</td>
<td>14</td>
<td>dysphagia/airway</td>
<td>cervical</td>
<td>Unknown</td>
<td>11</td>
<td>Yes</td>
<td>7.5 q3</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>3</td>
<td>m</td>
<td>25</td>
<td>12</td>
<td>spastic paraparesis¹</td>
<td>cervical</td>
<td>Yes</td>
<td>24</td>
<td>No</td>
<td>5 q3</td>
<td>Yes</td>
<td>No³</td>
<td>Yes</td>
</tr>
<tr>
<td>4</td>
<td>m</td>
<td>22</td>
<td>17</td>
<td>ataxic gait¹</td>
<td>cervical</td>
<td>Yes</td>
<td>36</td>
<td>Yes</td>
<td>5 q3</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>5</td>
<td>f</td>
<td>34</td>
<td>23</td>
<td>ataxic gait/paraparesis¹</td>
<td>cervical and thoracic</td>
<td>Yes</td>
<td>6</td>
<td>No</td>
<td>5 q2</td>
<td>Yes</td>
<td>Yes³</td>
<td>Yes</td>
</tr>
<tr>
<td>6</td>
<td>m</td>
<td>34</td>
<td>27</td>
<td>ataxic gait¹</td>
<td>cervical</td>
<td>Yes</td>
<td>6</td>
<td>No</td>
<td>5 q2</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>7</td>
<td>m</td>
<td>15</td>
<td>3</td>
<td>pain</td>
<td>cervical</td>
<td>Yes</td>
<td>58</td>
<td>Yes</td>
<td>5 q2</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>8</td>
<td>m</td>
<td>20</td>
<td>10</td>
<td>pain</td>
<td>cervical</td>
<td>Yes</td>
<td>16</td>
<td>Yes</td>
<td>5 q2</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

m: male, f: female, q3: every three weeks, q2: every two weeks
In addition to symptomatic ependymoma, patient also had progressive vestibular schwannoma.

Immunohistochemical staining of pre-treatment surgical specimen revealed the ependymoma was negative for VEGFR-1 and positive for VEGFR-2.

Immunohistochemical staining of pre-treatment surgical specimen revealed the ependymoma was positive for both VEGFR-1 and VEGFR-2.
**Fig. 1:** Spinal ependymoma (SE) in the cervical cord with a large cystic compartment (cy) of patient 4, shown with T2-weighted sagittal MRI (Siemens Avanto 1.5T).

**Fig. 2:** Immunohistochemical demonstration of VEGFR2 in spinal ependymoma of NF2 patients.

Varying expression of VEGF-R2 in three samples of NF2-associated ependymomas, both in the vasculature and the tumor tissue.
Fig. 3: Immunohistochemical demonstration of VEGFR-1 expression in spinal ependymoma of NF2 patients.

From left to right, tumor of patient 3, tumor of patient 5, three additional NF2-associated ependymomas from another case series; upper row, expression of VEGF-receptor in tumor endothelia; lower row, expression of VEGF-receptor in the tumor tissue; arrows indicate scattered positive cells.